FARS2 and MERRF syndrome: In contrast, the pathogenic G34A mutation within the anticodon loop of the substrate tRNAPhe, and associated with the MERRF syndrome, decreases the aminoacylation activity of hmit‐PheRS by 100‐fold (Fig. 2B) [34].